Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24373774 | 0.88 | IRAK4 (0.84) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25956596 | 0.87 | IRAK4 (0.83) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11701941 | 0.87 | IRAK4 (0.76) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25956604 | 0.87 | IRAK4 (0.78) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25956603 | 0.87 | IRAK4 (1.00) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3597174 | 0.85 | IRAK4 (1.00) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25956583 | 0.83 | IRAK4 (0.84) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25956581 | 0.83 | IRAK4 (0.84) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25967687 | 0.83 | IRAK4 (0.85) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25956589 | 0.83 | IRAK4 (0.85) | IRAK4NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-7132438-B2 | Benzimidazole derivatives | AMGEN INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | IRAK4 102/4885NPC1 4428/4885RAB9A 3690/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | IRAK4 55/4885NPC1 3547/4885RAB9A 4236/4885 |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | NFATC1, STAT1, IRF3 | IRAK4 55/4885NPC1 3547/4885RAB9A 4236/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885NPC1 3159/4885RAB9A 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.